Functional Longevity Labs, Inc. — SEC Form D Filing

Functional Longevity Labs, Inc. filed an SEC Form D on September 21, 2026, reporting $25K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
September 21, 2026
Amount reported
$25K
Round stage
Pre-Seed
Industry
Pharmaceuticals
Website
https://fll.health/

What the company does

Securities: Simple Agreement for Future Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

People experience an 'Health Gap'—a period between the end of healthy life and the end of life itself—due to the underlying biological mechanisms and individual manifestations of aging, leading to age-related illness, functional decline, and diseases like Alzheimer's.

Solution

Functional Longevity Labs is developing therapies, including a proprietary small molecule (FLL-01) for Alzheimer's disease and dietary supplements (Rejuveceuticals™) for age-related decline, by therapeutically modifying the root mechanisms of aging and specific targets like Tyrosyl-tRNA synthetase (TyrRS/YARS1).

Why now

Advances in geroscience, epigenetic biomarkers, and increased understanding of aging's biological mechanisms now allow for the development of targeted therapies to extend healthspan, moving beyond treating individual age-related diseases.

Verdict

This cleared because the team articulated a credible scientific wedge into the highly speculative longevity market, not because they presented a derisked commercialization strategy. Investors implicitly bet on the potential for novel biological insights to unlock a high-value therapeutic pathway, accepting the significant regulatory and development hurdles. Upside was constrained by the inherent early-stage nature of drug discovery, requiring extensive capital and time for validation, limiting the immediate commercial potential beyond an intellectual property play.

Source: SEC EDGAR Form D filing